James Oliviero, Checkpoint Therapeutics CEO

As push to dis­rupt PD-(L)1 pric­ing heats up, Check­point trum­pets a piv­otal suc­cess

The crowd­ed PD-(L)1 mar­ket has proven lu­cra­tive for bio­phar­ma’s ear­li­est en­trants like Mer­ck’s Keytru­da and Bris­tol My­ers Squibb’s Op­di­vo, but new­er drugs have strug­gled to pry away mar­ket share. One strat­e­gy be­ing un­der­tak­en by some biotech is to of­fer the drugs at a low­er price, and one such com­pa­ny claimed it’s now one step clos­er to ap­proval.

Check­point Ther­a­peu­tics re­vealed topline piv­otal da­ta for its an­ti-PD-L1 an­ti­body cosi­be­limab Tues­day morn­ing, say­ing the can­di­date achieved a 47.4% over­all re­sponse rate in metasta­t­ic cu­ta­neous squa­mous cell car­ci­no­ma pa­tients. The biotech has pre­vi­ous­ly in­di­cat­ed it could of­fer the drug at a 20% to 30% dis­count from the usu­al $150,000 price tag.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.